Mail Service Pharmacy

Similar documents
Drug Therapy Management

Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on an annual basis.

Pharmacy Benefit Management

Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on an annual basis.

MEASURE STEWARD Pharmacy Quality Alliance (PQA) D ATA SOURCE Enrollment; U R A C DOMAIN Engagement & Experience of Care

Disease Management. Measures At A Glance

2017 URAC PHARMACY BENEFIT MANAGEMENT PERFORMANCE MEASUREMENT: AGGREGATE SUMMARY PERFORMANCE REPORT

Disease Management. Measures At A Glance

PQS Summary of Pharmacy/ Medication-Related Updates in the CY 2020 Final Call Letter

PATIENT-IMPACT SCORECARD

PQA Measure Development Update: June 2017

Understanding Your Patient Care Opportunity Report (PCOR)

Proposed Changes to Existing Measure for HEDIS : Use of Opioids at High Dosage (UOD)

9/25/15. Pharmacy Quality Measures: Financial Support. Learning Objectives. Speaker Disclosure. Access to Preferred Networks and Clinical Performance

Telligen Quality Innovation Network Quality Improvement Organization

Legislative & Regulatory Update Brad Young, RxPlus Government Affairs

Coventry Health Care of Georgia, Inc.

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2018 (2018Q3)

Frequently Asked Questions (FAQ) IHA Align. Measure. Perform. (AMP) Programs January Audit Audit Roadmap Posted 1/23/19

Medicare Part D Prescription Opioid Policies for 2019 Information for Pharmacists

Alabama Medicaid Pharmacy Override

Drug Use Evaluation: Low Dose Quetiapine

STARS SYSTEM 5 CATEGORIES

April 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)

Medication trends shaping workers compensation. A 2018 update of the prevailing industry influences impacting pharmacy outcomes

Background. CMS finalized new policies for Medicare drug plans to follow starting on January 1,2019.

USING MTM TO IMPROVE STAR RATINGS : CASE STUDIES

PDMP Tools to Identify Red Flag Situations

Proposed Revision to Med (i)

Idaho DUR Board Meeting Minutes

The STOP Measure. Safe and Transparent Opioid Prescribing to Promote Patient Safety and Reduced Risk of Opioid Misuse FEBRUARY 2018

New Medicare Part D Prescription Opioid Policies for 2019 Information for Prescribers

Supporting Documentation

Prescription Drug Monitoring Program

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2017 (2017Q3)

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

HEDIS/QARR 2018 Quick Reference Guide ALL MEASURES

Adherence to Non-Infused Biologic Medications Used to Treat Rheumatoid Arthritis (PDC-RA)

SUBHEAD GOES HERE. Addressing Tennessee s Opioid Crisis. Natalie A. Tate, PharmD Vice President, Pharmacy

PHARMACY BENEFITS MANAGER SELECTION FAQ FOR PRODUCERS

Curbing Prescription Drug Abuse in Medicaid

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT FOURTH QUARTER OF 2017 (2017Q4)

MEASURING CARE QUALITY

Idaho DUR Board Meeting Minutes

Amy Larrick Chavez-Valdez, Director, Medicare Drug Benefit and C & D Data Group

General Providers. Tamper-Resistant Prescription Requirements

6/18/2015. Disclosure. Objectives. Star Ratings. Understand the current climate of healthcare reform

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.19

New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)

Medicare Star Ratings and the Shift to Quality- Based Payment Models. David Nau, RPh, PhD, FAPhA PQS President

Pain: Assessment, Non-Opioid Treatment Approaches and Opioid Management

Using the NC Controlled Substances Reporting System to Identify Providers Manifesting Unusual Prescribing Practices

Medication Management When Caring for Seniors at Home

The Morbidity and Mortality of Kansas Drug Epidemic

Cynthia B. Jones, Director Department of Medical Assistance Services (DMAS)

Medicare-Medicaid Data Integration (MMDI) Use Case: Profiling Potential Opioid Misuse among Dual Eligibles

PHARMACY COMPLIANCE RISK AREAS FOR 2014

Standard of Practice for Prescribing Opioids (Excluding Cancer, Palliative, and End-of-Life Care)

4/24/15. New Mexico s Prescription Monitoring Program. Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy. New Mexico and the PMP

SUMMARY TABLE OF MEASURES, PRODUCT LINES AND CHANGES

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.18

PBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S.

Pharmacy Audit Recovery Guidelines

Section I. Short-acting opioid Prior Authorization Criteria

Shining a Light on MEDs Understanding morphine equivalent dose

Strengthening our global leadership in treatment of addiction. Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018

Prescription Monitoring Program (PMP)

Challenges for U.S. Attorneys Offices (USAO) in Opioid Cases

Report to the Social Services Appropriations Subcommittee

USE OF OPIODS AT HIGHER DOSES IN PERSONS WITHOUT CANCER: MORPHINE EQUIVALENT DOSE EDIT

WHAT YOU NEED TO KNOW TO ABOUT AB 474

Lindsay Erickson, Director, Value Based P4P, Integrated Healthcare Association. Measurement Years 2016 & 2017 Proposed Changes to the VBP4P Program

VELTASSA (patiromer) oral suspension

Addressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention

Policy Evaluation: Substance Use Disorders

Safe Prescribing of Drugs with Potential for Misuse/Diversion

Doctor Shopping Behavior and the Diversion of Opioid Analgesics:

PCMH 2018 Enrollment and Update August 25, 2017

Condition/Procedure Measure Compliance Criteria Reference Attribution Method

REQUEST FOR MEDICARE PRESCRIPTION DRUG COVERAGE DETERMINATION This form may be sent to us by mail or fax:

Executive Summary. Classes Under Review: Analysis:

The University of Mississippi School of Pharmacy

MEASURING CARE QUALITY

Clinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46. Line of Business: Medicaid

Connecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting

Medicaid and the Opioid Crisis

Commercial HMO/POS Effectiveness of Care Measure

Greenbrier County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

Amal AL-Anazi, BSc.(Pharm) Medication Safety Officer In Eastern Region

OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES

Medicare Part D Opioid Policies for 2019 Information for Patients

Opioid prescription drug patterns in diagnosed and non-diagnosed opioid use disorder populations

Rule Governing the Prescribing of Opioids for Pain

Rethink. Adherence. David D. Pope, PharmD, CDE Editor-in-Chief, CreativePharmacist.com Brands

Maine s New Opioid Prescribing Law & the Opioid Crisis: Implications for Providers

Quality ID #438: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease National Quality Strategy Domain: Effective Clinical Care

Modernized Reference Drug Program

HEDIS Quick Reference Guide Updated to reflect NCQA HEDIS 2016 Technical Specifications

URINE DRUG TESTING FOR SUBSTANCE ABUSE TREATMENT AND CHRONIC PAIN MANAGEMENT

Transcription:

Mail Service s At A Glance Disclaimer: reserves the right to update its measures and measure sets to maintain measure relevancy and to remedy any unintended consequences that may arise during implementation. Further, may add and/or align its measures with regulatory requirements of federal, state, and local governments. Updated: 11/01/2018 2018 Page 1 of 12

Mandatory s (15) Mail Service Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to on an annual basis. # Name Description Numerator Denominator Source DM2012-12 Proportion of Days Covered (PDC) ; PH2018-01 Adherence to Long-Acting Inhaled Bronchodilator Agents in COPD Patients The percentage of patients 18 years and older who met the proportion of days covered (PDC) threshold of 80% during the A performance rate is calculated separately for the following medication categories: Betablockers (BB); Renin Angiotensin System Antagonists (RASA); Calcium Channel Blockers (CCB); Diabetes All Class (DR); Statins (STA); Anti-retrovirals (this measure has a threshold of 90% for at least 2 medications - ARV). The percentage of patients with COPD who met the Proportion of Days Covered (PDC) threshold of 80 percent during the period for longacting inhaled bronchodilator agents. A higher rate indicates better performance. Number of patients who met the PDC threshold for a target medication during the Number of patients who met the PDC threshold for a target medication during the Patients 18 years and older as of the last day of the year who filled at least two prescriptions for a target medication on two unique dates of service during the treatment Patients 18 years and older with a diagnosis of COPD and at least 2 prescription claims for any long-acting inhaled bronchodilator on unique dates of service during the treatment ; Disclaimer: reserves the right to update its measures and measure sets to maintain measure relevancy and to remedy any unintended consequences that may arise during implementation. Further, may add and/or align its measures with regulatory requirements of federal, state, and local governments. Updated: 11/01/2018 2018 Page 2 of 12

Mail Service # Name PH2018-02 Adherence to Non-Infused Biologic Agents to Treat Rheumatoid Arthritis (RA) PH2018-03 Adherence to Non-Infused Disease- Modifying Agents Used to Treat Multiple Sclerosis (MS) Description Numerator Denominator Source The percentage of patients with 18 years and older with rheumatoid arthritis (RA) who met the Proportion of Days Covered (PDC) threshold of 80 percent during the period for biologic medications used to treat RA. A higher rate indicates better performance. The percentage of patients with 18 years and older who met the Proportion of Days Covered (PDC) threshold of 80 percent during the period for disease-modifying agents used to treat multiple sclerosis (MS). A higher rate indicates better performance. Number of patients who met the PDC threshold for a target medication during the Number of patients who met the PDC threshold for a target medication during the Patients 18 years and older with a rheumatoid arthritis (RA) diagnosis during the year AND two or more prescription claims for non-infused biologic medications used to treat RA on two unique dates of service, for which the sum of the days supply is 56 days or greater during the treatment Patients who filled at least two prescriptions for non-infused disease modifying agents used to treat MS on two unique dates of service in the treatment period AND who received at least 56 cumulative day s supply of the medication during the treatment ; ; Disclaimer: reserves the right to update its measures and measure sets to maintain measure relevancy and to remedy any unintended consequences that may arise during implementation. Further, may add and/or align its measures with regulatory requirements of federal, state, and local governments. Updated: 11/01/2018 2018 Page 3 of 12

Mail Service # DTM2015-01 Name Adherence to Non-Warfarin Oral Anticoagulants Description Numerator Denominator Source percentage of patients 18 years and older who met the Proportion of Days Covered (PDC) threshold of 80% during the period for non-warfarin oral anticoagulants. A higher rate indicates better performance. The number of patients who met the PDC threshold during the Patients who filled at least two prescriptions for a nonwarfarin oral anticoagulant on two unique dates of service at least 180 days apart during the treatment period AND who received greater than 60 days supply of the medication during the treatment ; DM2012-13 Drug-Drug Interactions Safe Care percentage of patients who received a prescription for a target medication during the period and who were dispensed a concurrent prescription for a precipitant medication. The number of patients in the denominator who were dispensed a concurrent precipitant medication during the Patients who received a target medication. Claims; MP2012-09 Generic Dispensing Rates Health Care Mgmt percentage of all prescriptions that were dispensed as generics, branded generics, or brands for which members paid the generic co-pay. Total number of prescriptions in the denominator as dispensed as generics. Total number of prescription claims available in generic form (i.e., multi-source) that were dispensed during the Disclaimer: reserves the right to update its measures and measure sets to maintain measure relevancy and to remedy any unintended consequences that may arise during implementation. Further, may add and/or align its measures with regulatory requirements of federal, state, and local governments. Updated: 11/01/2018 2018 Page 4 of 12

Mail Service # DTM2010-04 Name Call Center Performance Health Care Mgmt Description Numerator Denominator Source This measure has two parts: Part A evaluates the percentage of calls during normal business hours to the organization s call service center(s) during the period that were answered by a live voice within 30 seconds; Part B evaluates the percentage of calls made during normal business hours to the organization s call service center(s) during the reporting year that were abandoned by callers before being answered by a live customer service representative. Part A: The number of calls answered by a live customer service representative within 30 seconds of being placed in the organization's ACD call queue. Part B: The number of calls abandoned by callers after being placed in the ACD call queue and before being answered by a live customer service representative. Total number of calls received by the organization's call service center during normal business hours during the Automatic Call Distribution (ACD) [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] Disclaimer: reserves the right to update its measures and measure sets to maintain measure relevancy and to remedy any unintended consequences that may arise during implementation. Further, may add and/or align its measures with regulatory requirements of federal, state, and local governments. Updated: 11/01/2018 2018 Page 5 of 12

# MP2012-06 MP2012-07 Name Dispensing Accuracy Distribution Accuracy Mail Service Description Numerator Denominator Source Safe Care This six-part measure and Part A: The number of drugs and Total number of composite roll-up assesses the products in the denominator in which drugs and percentage of prescriptions an incorrect drug and/or product was products that the organization dispensed. dispensed by the dispensed inaccurately. Part B: The number of drugs and organization to or products in the denominator that were on behalf of a parts include: (A) dispensed to an incorrect recipient. specific patient Incorrect Drug and/or Product Part C: The number of prescriptions in during the Dispensed; (B) Incorrect the denominator that were dispensed Recipient; (C) Incorrect at an incorrect strength. Strength; (D) Incorrect Dosage Part D: The number of prescriptions in Form; (E) Incorrect the denominator that were dispensed Instructions; (F) Incorrect in an incorrect dosage form. Quantity. Part E: The number of drugs and products in the denominator that were dispensed with incorrect patient instruction. Part F: The number of drugs and products in the denominator that were dispensed as an incorrect quantity. Roll up Methodology: Sum numerator from Parts A - F. Safe Care percentage of prescriptions delivered to the wrong recipient. Part A measures the percentage of prescriptions mailed with an incorrect address; Part B measures the percentage of prescriptions mailed with a correct address that were not delivered to the correct location. Part A: The number of drugs and products dispensed with an incorrect address. Part B: The number of drugs and products delivered to the wrong location despite having the correct address on the package. Total number of drugs and products dispensed by the organization to or on behalf of a specific patient during the ; Disclaimer: reserves the right to update its measures and measure sets to maintain measure relevancy and to remedy any unintended consequences that may arise during implementation. Further, may add and/or align its measures with regulatory requirements of federal, state, and local governments. Updated: 11/01/2018 2018 Page 6 of 12

Mail Service # MP2012-08 Name Turnaround Time for Prescriptions Health Care Mgmt Description Numerator Denominator Source This 3-part measure assesses the average speed with which the organization fills new and refill prescriptions. Part A measures prescription turnaround time for new and refill clean prescriptions; Part B measures prescription turnaround time for new and refill prescriptions that required intervention; and Part C measures prescription turnaround time for all new and refill prescriptions. Part A, B, C: The sum of business days to fill new and refill prescriptions in the denominator (n1 + n2 + nx, where n1 = the number of business days to schedule delivery of prescription 1, n2 = the number of business days to schedule delivery of prescription 2 nx = the number of business days to schedule delivery of prescription x). Part A: Total number of drugs and products that arrived clean and that the organization filled during the Part B: Total number of prescriptions that initially required intervention and that the organization filled during the Part C: Total number of prescriptions the organization filled during the Disclaimer: reserves the right to update its measures and measure sets to maintain measure relevancy and to remedy any unintended consequences that may arise during implementation. Further, may add and/or align its measures with regulatory requirements of federal, state, and local governments. Updated: 11/01/2018 2018 Page 7 of 12

# Name PH2018-04 Concurrent Use of Opioids & Benzodiazepines Patient Safety Mail Service Description Numerator Denominator Source The percentage of individuals 18 years and older with concurrent use of prescription opioids and benzodiazepines. A lower rate indicates better performance. The number of individuals from the denominator with two (2) or more prescription claims for any benzodiazepines on unique dates of service, AND concurrent use of opioids and benzodiazepines for 30 or more cumulative days. Individuals with 2 or more prescription claims for opioids on unique dates of service, for which the sum of the days supply is 15 or more days supply during the ; ; RxHCCs PH2018-05 Polypharmacy: Use of Multiple Anticholinergic Medications in Older Adults Patient Safety The percentage of adults 65 years and older with concurrent use of 2 or more unique anticholinergic medications. A lower rate indicates better performance. The number of individuals from the denominator with concurrent use for 30 or more cumulative days of 2 or more unique anticholinergic medications, each with 2 or more prescription claims on unique dates of service during the Individuals with 2 or more prescription claims for the same anticholinergic medication on unique dates of service during the ; Disclaimer: reserves the right to update its measures and measure sets to maintain measure relevancy and to remedy any unintended consequences that may arise during implementation. Further, may add and/or align its measures with regulatory requirements of federal, state, and local governments. Updated: 11/01/2018 2018 Page 8 of 12

Mail Service # Name Description Numerator Denominator Source PH2018-06 Polypharmacy: Use of Multiple CNS-Active Medications in Older Adults Patient Safety The percentage of adults 65 years and older with concurrent use of 3 or more unique central-nervous system (CNS) active medications. A lower rate indicates better performance. The number of individuals from the denominator with concurrent use for 30 or more cumulative days of 3 or more unique CNS-active medications, each with 2 or more prescription claims on unique dates of service during the Individuals with 2 or more prescription claims for the same CNS-active medication on unique dates of service during the ; Disclaimer: reserves the right to update its measures and measure sets to maintain measure relevancy and to remedy any unintended consequences that may arise during implementation. Further, may add and/or align its measures with regulatory requirements of federal, state, and local governments. Updated: 11/01/2018 2018 Page 9 of 12

Mail Service # Name Description Numerator Denominator Source PH2018-08 Use of Opioids at High Dosage or from Multiple Providers in Persons Without Cancer Patient Safety Three (3) measures that examine high dosage opioid use from multiple providers, among individuals 18 years and older without cancer. 1: Use of Opioid at High Dosage in Persons Without Cancer (OHD): The proportion (XX out of 1,000) of individuals from the denominator receiving prescriptions for opioids with a daily dosage greater than 120 morphine milligram equivalents (MME) for 90 consecutive days or longer. 2: Use of Opioids from Multiple Providers in Persons Without Cancer (OMP): The proportion (XX out of 1,000) of individuals from the denominator receiving prescriptions for opioids from four (4) or more prescribers AND four (4) or more pharmacies. 3: Use of Opioids at High Dosage and from Multiple Providers in Persons Without Cancer (OHDMP): The proportion (XX out of 1,000) of individuals from the denominator receiving prescriptions for opioids with a daily dosage greater than 120 morphine milligram equivalents (MME) for 90 consecutive days or longer, AND who received opioid prescriptions from four (4) or more prescribers AND four (4) or more pharmacies. 1: The number of individuals from the denominator with greater than 120 MME for 90 or more consecutive days. 2: Any member in the denominator who received opioids from 4 or more prescribers AND 4 or more pharmacies. 3: Any member in the denominator with greater than 120 MME for 90 days or more consecutive days AND who received opioids from 4 or more prescribers AND 4 or more pharmacies. 1, 2, & 3: Individuals with 2 or more prescription claims for opioids on unique dates of service, for which the sum of the days supply is 15 or more days supply during the Medical Claims; ; RxHCCs; ICD-10s Disclaimer: reserves the right to update its measures and measure sets to maintain measure relevancy and to remedy any unintended consequences that may arise during implementation. Further, may add and/or align its measures with regulatory requirements of federal, state, and local governments. Updated: 11/01/2018 2018 Page 10 of 12

Mail Service Exploratory s (6) Note: Exploratory measures are measures on the cutting edge, meaning that either the industry has not come to consensus on how to measure a particular concept or the measure is experimental or in development. In the case of exploratory measure, the organization has the option to report. # Name SP2012-09 Fulfillment of Promise to Deliver Health Care Mgmt Description Numerator Denominator Source percentage of prescriptions that the organization delivered on time (i.e., the percentage of prescriptions that reached patients on the date scheduled for delivery). Number of prescriptions in the denominator that patients received on the date scheduled for delivery. Total number of prescriptions that the organization filled during the Administrative ; HIM2013-21 PH2015-01 Use of High-Risk Medications in the Elderly (HRM) Primary Medication Non-Adherence Safe Care percentage of patients 65 years of age and older who received two or more prescription fills for a high-risk medication during the Stratify by Commercial, Medicaid, and Medicare (i.e., report each product line separately). The percentage of prescriptions for chronic medications e- prescribed by a prescriber and not obtained by the patient in the following 30 days. This rate measures the level of primary medication non-adherence across a population of patients. The number of patients who received at least two prescription fills on different dates of service for the same high-risk medication during the The number of e- prescribing transactions in the denominator where there was no pharmacy dispensing event that matched the patient and the prescribed drug or appropriate alternative drug within 30 days following the e-prescribing event. Members 66 years or older on the last day of the year and continuously enrolled during the The number of e- prescriptions for newly initiated drug therapy for medications in Table A: Chronic Medications for PMN during the period and for the eligible population. Claims; Prescription Claims ; e- Prescribing Disclaimer: reserves the right to update its measures and measure sets to maintain measure relevancy and to remedy any unintended consequences that may arise during implementation. Further, may add and/or align its measures with regulatory requirements of federal, state, and local governments. Updated: 11/01/2018 2018 Page 11 of 12

Mail Service # Name PH2015-03 Use of Benzodiazepine Sedative Hypnotic Medications in the Elderly Safe Care Description Numerator Denominator Source percentage of individuals 65 years of age and older that received two or more prescription fills for any benzodiazepine sedative hypnotic for a cumulative period of more than 90 days. Individuals in the denominator who received two prescriptions for any benzodiazepine sedativehypnotic medication and a cumulative days supply of greater than 90 days for any benzodiazepine sedative hypnotic during the Members 65 years or older on the first day of the Claims; PH2015-06 Statin Use in Persons with Diabetes Prevention & Treatment percentage of patients ages 40-75 years who were dispensed a medication for diabetes that receive a statin medication. Stratify by Commercial, Medicaid, and Medicare (i.e., report each product line separately). The number of eligible patients who received one or more prescription fills for a statin during the The number of eligible patients who were dispensed two or more prescription fills for a diabetic medication during the Claims; PH2015-05 Consumer Experience with Services Survey s: Staff Communication, Information about Medicine, Written Information, New Prescriptions, and About You. N/A N/A PQA Survey Disclaimer: reserves the right to update its measures and measure sets to maintain measure relevancy and to remedy any unintended consequences that may arise during implementation. Further, may add and/or align its measures with regulatory requirements of federal, state, and local governments. Updated: 11/01/2018 2018 Page 12 of 12